- About About
Medical Patient Resources Becoming a State-Authorized Patient Talking to your doctor Which conditions qualify? The Medical Cannabis Patient’s Guide for U.S. Travel Patient's Guide to CBD Patient's Guide to Medical Cannabis Guide to Using Medical Cannabis Condition-based Booklets Growing Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Leaf411 Affordability Program Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources CME for Medical Professionals Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
- News News
Policy Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Reports 2020 State of the States Medical Cannabis Access for Pain Treatment Medical Cannabis in America Recognizing Science using the Data Quality Act Fact Sheet on ASA's Data Quality Act Petition to HHS Data Quality Act Briefs ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit
- Join Join
Policy Recommendations Delaware
2019-2020 Improvements and Recommendations for Delaware
Newly authorized Compassionate Use Cards (CUSs) will be issued to eligible applying patients and will specifically indicate the type of cardholder (e.g. physician, patient, caregiver, etc). Patients and their physicians must submit information to the Division of Public Health indicating that the patient has a severe and debilitating condition and that current standard care practices and treatments have been exhausted. In 2020, Delaware implemented emergency features to the state's medical access model, declaring cannabis businesses essential, allowing for telehealth visits for patient registrations, and authorizing both curbside pickup and delivery.
Delaware licensed only six retailers, which are owned by the same three ownership groups. Patient access is negatively impacted in a number of ways as a result of this oligopoly arrangement. Core issues include inadequate and inconsistent supply of critical medicine to treat patient conditions, lack of medical cannabis product consistency, excessive pricing and lack of product availability in larger quantities.
Delaware lawmakers should expand the number of retail access points, impose requirements on retail operators to maintain sufficient quantities and varieties of products, and provide for sufficient patient engagement accommodations (e.g. seating, pre-order capability for curbside pickup). ASA also encourages the state to make improvements to lab testing regulations, product safety protocols, and product labeling requirements. Lab testing should include an analysis of the volume of specific cannabis compounds in the product (e.g. THC, CBD, CBG) and related terpenes, and included on all product labels. ASA also encourages the state to maintain COVID emergency program additions.